04.07.21 -- AI Speeds Patient Recruitment At Health Quest
On this episode of Business of Biotech, Nevan Charles Elam, J.D., founder of Rezolute Bio, shares the company's rationale for pursuing congenital hyperinsulinism and diabetic macular edema therapeutics by leveraging monoclonal antibodies (mAbs) and discusses the company's approach to process development and manufacturing. Listen now and subscribe so you never miss an episode. Featured Editorial By Ed Miseta, chief editor, Clinical Leader Artificial intelligence (AI) has the potential to disrupt and revolutionize many aspects of clinical trials. One area in which it is already making an impact is patient recruitment. Mining electronic medical records (EMRs) for patients meeting inclusion and exclusion criteria can be tedious and time-consuming work but is a chore that seems ideal for an AI solution.